Object. The utilization of endovascular treatment for ruptured intracranial aneurysms is expected to change since the publication of the International Subarachnoid Aneurysm Trial (ISAT) in 2002. The authors performed this analysis to determine the impact of ISAT results on treatment selection for ruptured intracranial aneurysms and associated in-hospital outcomes using nationally representative data.
S
ince the introduction of endovascular treatment for intracranial aneurysms, 25, 27 multiple studies have evaluated the national trends in utilization and outcomes for patients with SAH. 1, 13, 28, 29 We previously reported the change in utilization of endovascular treatment and associated outcomes among patients admitted in 1990-1991 and those admitted in 2000-2001 in the US. 29 Subsequently, 2 studies 1, 13 reported upon the trends in utilization of endovascular treatment and associated outcomes among patients admitted from 1993 through 2003. In 2002, the results of the multicenter Phase III International Subarachnoid Aneurysm Trial (ISAT) 22 were reported. The study compared the efficacy of endovascular treatment with surgical treatment in 2143 patients with ruptured aneurysms suitable for either treatment. Recruitment was prematurely stopped after a planned interim analysis showed reduced disability in the endovascular treatment group. A higher proportion of patients allocated to surgery (31% of 793) were dependent or dead at 1 year compared with patients allocated to endovascular treatment (24% of 801). In 2003, after the results of the ISAT were published, the American Society Impact of International Subarachnoid Aneurysm Trial results on treatment of ruptured intracranial aneurysms in the United States of Interventional and Therapeutic Neuroradiology and the American Society of Neuroradiology, 8 the German Society of Neurosurgery, 30 and the National Institute of Clinical Excellence 23 guidelines endorsed endovascular therapy as a treatment option for patients with a ruptured cerebral aneurysm. In August 2003, the FDA approved the use of Guglielmi detachable coils (GDC, Boston Scientific Corp.) to treat all brain aneurysms, 26 expanding the previous (1995) approval for use in aneurysms that are high surgical risks. Subsequent to the publication of the ISAT trial results and incorporation of these results in statements and policies of professional and regulatory organizations, changes in utilization of endovascular treatment, and even patient outcomes are expected to occur.
Nevertheless, the applicability of the results to patient populations outside clinical trials, particularly within the US, has been questioned widely, 2, 3, 11, 16, 35 potentially limiting the impact of the study results on clinical practice. Of 9559 patients with ruptured intracranial aneurysms assessed for eligibility, 7146 patients were not randomized in the ISAT, and more of these patients underwent neurosurgical treatment than endovascular treatment for the ruptured aneurysms. 2, 3, 11 Another review identified discrepancies between the ISAT results and results of 19 other published studies, with procedural limitations in study design and lack of some data end points and subgroup analysis raising concerns regarding application of ISAT results. 9 An overall assessment of the ISAT by many neurosurgeons concluded that neurosurgical treatment was and probably will continue to be the most frequently used option for patients with ruptured intracranial aneurysms. 2, 3, 11 The outcome and economic data obtained in the US at 1 year after the procedure also suggested that endovascular treatment is more costly than the neurosurgical alternative, which may affect widespread availability of the procedure. 20 We performed this study to test the hypothesis that there is an increase in utilization of embolization with subsequent improvement in overall SAH patient outcomes in clinical practice subsequent to publication of the ISAT results.
Methods
We used the data from the Nationwide Inpatient Sample (NIS) which is part of the Healthcare Cost and Utilization Project (HCUP) sponsored by the Agency for Healthcare Research and Quality (AHRQ). 21, 34 The NIS is the largest all-payer inpatient care database in the US and was designed to identify, track, and analyze national trends in health care utilization, access, charges, quality, and outcomes. It contains data from approximately 5-8 million hospital stays representing approximately a 20% stratified sample of US hospitals. The NIS is the only national hospital database with charge information on all patients, regardless of payer, including patients covered by Medicare, Medicaid, and private insurance, and those who are uninsured. Detailed information on the design of the NIS is available at http://www.hcup-us.ahrq.gov. The NIS database has data on more than 100 clinical and nonclinical variables associated with hospital stays, including primary and secondary diagnoses, primary and secondary procedures, patients' admission and discharge status, patient demographic information (for example, sex, age, race, median income for ZIP code), expected payment source, total charges, and LOS.
We used the NIS data to estimate the numbers of hospitalization for SAH; the proportion of various in-hospital outcomes, including cost; and mortality associated with admissions of patients with SAH. Diagnostic code fields were screened for ICD-9-CM code 430 to identify patients aged 18 years or older with SAH as primary diagnoses. Patients with head trauma (secondary diagnosis of ICD-9-CM codes 800.0-801. 9 19 ), transfusion of packed red blood cells (ICD-9-CM 99.04), angioplasty for vasospasm (ICD-9-CM 39.50), cerebral angiography (ICD-9-CM 88.41), injection or infusion of thrombolytics (ICD-9-CM 99.10), and intraarterial infusion of therapeutic medication (ICD-9-CM 99.29). Possible procedure-related complications included occlusion of a cerebral artery with or without infarction (ICD-9-CM 434.0-434.9); postoperative neurological complications, including infarction or hemorrhage (ICD-9-CM 997.00-997.09); postoperative cardiac complications (ICD-9-CM 997.1); postoperative respiratory insufficiency (ICD-9-CM 518.5); and hematoma complicating a procedure (ICD-9-CM 998.1-998.13).
For the first period, we looked at data from 2000-2002, before the results of ISAT were available (pre-ISAT period); by 2004-2006 the ISAT results were published (post-ISAT period). The variables abstracted were patients' age, sex, race/ethnicity, LOS, discharge status (categorized into routine, home health care, short-term hospital, other facility including intermediate care and skilled nursing home, or death); and medical complications; procedures performed; total cost of hospitalization; and characteristics of the hospitals in which the patients were treated (rural, urban nonteaching, and urban teaching hospitals). The NIS defines an urban hospital as one located in a metropolitan statistical area and a teaching hospital as one with American Medical Association-approved residency program and either membership in the Council of Teaching Hospitals or a ratio of full-time equivalent interns and residents to beds of 0.25 or higher. To account for the effect of inflation on hospital charges, we used data from the Bureau of Labor Statistics' medical care component of the Consumer Price Index (http:// www.bls.gov/cpi/). In addition, we converted hospital charges into hospital costs using the cost-to-charge ratio estimates, which are constructed using all-payer, inpatient cost, and charge information from the detailed reports by hospitals to the Centers for Medicare and Medicaid Services. Data are presented in 2006 US dollars after adjustment for inflation.
We used the chi-square test for categorical data and analysis of variance for continuous data to detect any significant differences in the distribution of hospitals' and patients' characteristics between the 2000-2002 and 2004-2006 time periods. We evaluated whether changes over time of in-hospital outcomes (LOS, hospital costs, and in-hospital mortality) were different across patients undergoing different procedures (interaction effect). In addition, the overall period effect and the period effect for each procedure practice were estimated. We used multivariable models to account for imbalances in the distribution of hospital and patient characteristics. We adjusted for potential confounders that included myocardial infarction, coma, hydrocephalus, hyponatremia, patient age, and type of hospital in every multivariable model. For LOS and hospitalization cost, we analyzed outcomes using re- gression analysis for sample survey data. Outcomes were analyzed in natural log scale and retransformed to present geometrical means. For in-hospital mortality, analysis was performed using logistic regression for sample survey data. We evaluated the procedure × time interaction by specifying the main effects (procedure and time) in addition to the interaction, and used a 2-degree F test to evaluate significance for LOS and hospital costs and a 2-degree Wald chi-square test for in-hospital mortality). Analysis was repeated without the interaction effect to evaluate overall time change, and within-each-procedure time change. In addition, we evaluated whether outcomes followed a linear trend, by modeling year as a continuous variable and by adding a quadratic term. Statistical significance is reported for the linear trend, and results from quadratic models are omitted because there was no observed significance. We used the SAS 9.1 software (SAS Institute Inc.) to convert raw counts generated from the NIS database into weighted counts that we used to generate national estimates. All analyses accounted for the complex sampling design and sample discharge weights of the NIS following HCUP-NIS recommendations (HCUP Methods Series Report No. 2003-2). A probability value < 0.01 was considered to be statistically significant to avoid overstating associations due to multiple comparisons in a large data set. In addition, we performed an exploratory analysis to evaluate the population-attributable fraction to identify the mortality occurring due to lack of any aneurysm treatment (endovascular or neurosurgical) for the 2 time periods. The population-attributable fraction was calculated as p × (1−1/OR), where p is the proportion of patients not being treated and OR is the odds ratio derived based on the differential rate of in-hospital death between treated and untreated patients obtained from the logistic regression model with corresponding adjustment.
Results
We estimated that there were 70,637 admissions for SAH in US hospitals between 2000 and 2002. There were 77,352 such admissions between 2004 and 2006, which represents a 9% increase (Fig. 1) . Patient characteristics were similar in both periods ( Table 1 ). The distribution of types of hospitals treating patients with ruptured intracranial aneurysms changed (p = 0.005); the number of patients treated at urban teaching hospitals increased from 65% in 2000-2002 to 73% in [2004] [2005] [2006] . Some complications associated with SAH were more prevalent in the post-ISAT period. These included hydrocephalus, hyponatremia, and hypernatremia. There was a change in the procedures performed between the 2 periods (p < 0.0001); an increase in endovascular procedures in the post-ISAT period (3% vs 17%), a decrease in surgical procedures (31% vs 23%), and a nonsignificant increase in proportion of patients who get any treatment (surgical or endovascular) (see Fig. 2 ). There was no significant difference in the rates of other procedures, except for angioplasty (1.5% vs 2.2%, p = 0.007). The rates of postoperative complications (see Table 1 ) were similar between the 2 time periods. The discharge pattern differed significantly between periods (p < 0.0001). The proportion of patients discharged home was higher among those admitted in post-ISAT period compared with those admitted in pre-ISAT period (35% vs 32%); and the proportion of patients who died was lower among those admitted in post-ISAT period compared with those admitted in pre-ISAT period (24% vs 27%).
In the interaction models, the association of time period with hospital cost was modified by the treatment practice (p = 0.0007, interaction test) (see Table 2 ). The cost for patients undergoing an endovascular procedure increased more than the cost for patients undergoing a surgical procedure during the post-ISAT period (percentage change: 24%, 95% CI 5%-50% vs 7%, 95% CI 1%-15%, p = 0.04), while the cost for patients who did not undergo any aneurysm treatment procedure remained constant. Changes in LOS and in-hospital mortality between periods did not differ significantly according to procedure practice. However, a prominent reduction of in-hospital mortality was observed in the post-ISAT period among patients undergoing endovascular procedures (OR 0.79, 95% CI 0.58-1.1) and those who did not undergo any aneurysm treatment procedure (OR 0.57, 95% CI 0.52-0.60) but not among patients undergoing surgical treatment (OR 0.97, 95% CI 0.83-1.1). Changes in LOS between periods, though statistically significant, were less than 1 day for any procedure group. Overall, the only significant change between periods was observed for in-hospital mortality (OR 0.89, 95% CI 0.83-0.96, p = 0.003). Linear trends during the period from 2000 to 2006 were observed for LOS and in-hospital mortality.
The exploratory analysis of population-attributable fraction estimates suggested that the proportion of inhospital deaths attributable to lack of aneurysm treatment (endovascular or neurosurgical) was lower in the post-ISAT period than in the pre-ISAT period (34% vs 39%, absolute difference of 5%).
Discussion
We observed a prominent increase in utilization of endovascular treatment (3% vs 17%) for intracranial aneurysms and an increase in the proportion of patients who received any treatment (33% vs 40%) in the post-ISAT period. It may be possible that the observed increase was a part of a more gradual increase in utilization of endovascular procedures independent of the ISAT results. We had previously compared the hospitalization patterns and outcomes among stroke patients admitted in 1990-1991 or 2000-2001 using the NIS. 29 The NIS is the same data set used for the current analysis. Table 1 ). The increase in utilization of endovascular procedures (6-fold in 2 years) appears out of proportion to the expected rise in utilization based on previously observed trends. However, there have been substantial improvements in endovascular technology, such as bioactive coils, expandable coils, and complex-shaped coils during the same period, which may account for some of observed increase in utilization. 19 In addition to Guglielmi detachable coils (GDCs, Boston Scientific Corp.), several other detachable coils with unique attributes, including Matrix (Boston Scientific), Trufill DCS Orbit (Codman Neurovascular), Axium (ev3 Inc.), HydroCoil (MicroVention Terumo), and Micrus Endovascular Microcoil (Micrus Endovascular Corp.), and 2 flexible stents, Neuroform (Boston Scientific Corp.) and Enterprise (Codman Neurovascular), became available. The increase in the spectrum of aneurysms that can be treated and the durability of embolization is widely recognized, 19 but the exact impact upon the trends observed is not known.
We also observed a reduction in the in-hospital mortality in the post-ISAT period. In our previous comparison between the hospital outcomes among SAH patients admitted in 1990-1991 and 2000-2001, the in-hospital mortality was reduced from 29.4% to 26.5% over a 10-year period. 29 A further reduction was observed with the in-hospital mortality estimated at 25% in the post-ISAT period. Presumably, the decrease in mortality was due to a larger proportion of patients receiving any treatment and endovascular treatment, thus reducing the rate of rebleeding and associated mortality. 5 It is not possible to exclude that the observed reduction in mortality may be due to improvement in overall care of SAH patients with time. The reduction in mortality (although of a lesser magnitude) among untreated patients also supports the role of other medical interventions. In an exploratory analysis, a 5% reduction in the rate of in-hospital deaths attributable to not performing a procedure between periods, based on population-attributable risk estimates, suggests a relationship between a higher proportion of patients receiving any treatment and lower mortality. Another important factor was the increase in the rate of admission to urbanteaching hospitals in the post-ISAT period, which could explain the reduction in mortality. Admission to urbanteaching hospitals has been associated with lower mortality in a previous analysis. 29 It is likely that an increased admission to urban-teaching hospitals is a consequence of increased utilization of endovascular procedures.
It has been previously observed that patients recruited in clinical trials have more favorable characteristics than those treated in clinical practice (cherry-picking phenomenon). 26 While such selection criteria are required to ensure relative homogeneity of study population and avoid obscuring of treatment effect by poor clinical condition of patients, there are implications for generalization of results. The overall in-hospital mortality was 6% in ISAT 22 compared with the 26% in-hospital mortality observed for SAH in the United States 28 and 22% in-hospital mortality in the Japanese Standard Stroke Registry Study. 14 These observations suggest that patients treated in the ISAT had more favorable baseline clinical and procedural characteristics compared with those observed in general population questioning generalization of results. 26 The reduction in mortality and rate of discharge to a long-term facility in the post-ISAT period suggests that the benefit observed in the ISAT may be seen when the results are applied to modify practice patterns. The benefits of endovascular treatment are somewhat obscured in SAH patients in uncontrolled observational studies presumably due to preferential treatment of patients classified as poor grade in whom outcome is predominantly determined by initial clinical condition.
The impact of ISAT has been studied in single-center studies. A study from a neurosurgical unit in the United Kingdom 10 reported that the proportion of patients undergoing surgical treatment decreased from 51% to 31% while endovascular treatment of aneurysms increased from 35% to 68% since publication of ISAT results. Over the same time points, there was a nonsignificant trend toward better outcomes at 6-month follow-up and a decrease in the mean total duration of hospital stay. Another study 18 analyzed the therapeutic decision-making process and outcomes in 100 consecutive patients with SAH treated since the publication of the ISAT. Forty-seven patients underwent surgical treatment, 41 underwent endovascular treatment, and 12 a combination of the 2 procedures. Good functional outcome (modified Rankin Scale Score 0-2) after 6 months was achieved in 71% of patients. The study suggested that in routine clinical practice, excellent functional results could be seen with complementary surgical and endovascular treatments using the ISAT data to assign treatment selection.
We used the data from the NIS, a large-size data set used in previous stroke studies with standardized design, to provide a representative estimate of the total hospitalizations of US experience. 21, 34 However, the database provides minimal details on severity of neurological deficits, diagnostic study results, and use of procedures. The NIS data also depend on the accuracy of diagnoses and procedures listed on discharge summaries and on the data collection system. The accuracy of the primary diagnosis of ICD-9-CM code 430 used for identifying SAH admissions was found to have a high accuracy (86%) in the Atherosclerosis Risk in Communities study. 32 Williams et al. 36 reported that the positive predictive value of ICD-9-CM primary or secondary diagnosis code 430 was 83%. We may have underestimated the number of SAHs because we only used the primary diagnosis code, which has high specificity but underestimates the number of admissions. 4 The issue of not capturing procedures due to inadequate code utilization is important because the overall proportion of patients with SAH treated with either modality in our study was approximately 40% of all admissions, similar to other studies based in administrative data. 6, 7 The rates of any treatment (neurosurgical or endovascular) in population-based SAH-patient studies using case ascertainment by chart review have ranged from 38% to 70%. 15, 24, 31 The relatively low rate of treatment is presumably attributable to nonaneurysmal SAH accounting for up to 52% of cases 33 and early mortality (within 24 hours) reported in up to 22% of cases of nontraumatic SAH. 24 We used the same procedure codes to identify endovascular and neurosurgical procedures as used in previous studies. 12, 13, 17 Johnston et al. 17 determined the accuracy of ICD-9-CM procedure codes by comparing extensive chart review and matching records in the University Health System Consortium database and found that procedure type was incorrectly coded in only 4 (2%) of 179 cases listed in the database. Certain variables, such as cerebral vasospasm, hydrocephalus, hypernatremia, and hyponatremia, were identified by ICD-9-CM codes based on documentation in the chart and lacked standard definitions. The discharge functional outcome cannot be measured with the available data, and the closest index is the destination of discharge. Therefore, limited comments can be made regarding disability incurred with SAH.
Conclusions
The study demonstrates that the ISAT results have been associated with a prominent change in practice patterns related to ruptured aneurysm treatment in the US with a favorable impact on patient outcomes.
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